In this issue:
Evobrutinib versus teriflunomide
Efgartigimod PH20 safety, tolerability and efficacy
Association between MOGAD, MOG-IgG and relapse risk
Long-term outcomes of MOGAD
S1P-RM compared to natalizumab
Factors influencing treatment responses in CIDP
Anti-CGRP monoclonal antibodies and its responses
Initial corticosteroid regimen use and treatment response
Efficacy of efgartigimod
Categorising hypothalamic involvement
Please login below to download this issue (PDF)